Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | NAT1 | P18440 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 3/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 8/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10519622 | 0.82 | PIM1 (0.74) | IDH1MMP13MMP3NAT1GSK3B | |
| SCHEMBL10519629 | 0.82 | PIM1 (0.74) | IDH1MMP13MMP3NAT1GSK3B | |
| SCHEMBL8173392 | 0.81 | MMP13 (0.68) | IDH1MMP13MMP3NAT1GSK3B | |
| SCHEMBL8173395 | 0.81 | MMP13 (0.68) | IDH1MMP13MMP3NAT1GSK3B | |
| SCHEMBL13846891 | 0.81 | IDH1 (0.68) | IDH1MMP13MMP3NAT1GSK3B | |
| SCHEMBL21339675 | 0.80 | IDH1 (0.67) | IDH1MMP13MMP3NAT1GSK3B | |
| SCHEMBL21538211 | 0.78 | IDH1 (0.64) | IDH1 | |
| SCHEMBL17140247 | 0.76 | ADAMTS5 (0.84) | MMP13MMP3NAT1GSK3BADAMTS5 | |
| SCHEMBL1726213 | 0.76 | ADAMTS5 (0.84) | MMP13MMP3NAT1GSK3BADAMTS5 | |
| SCHEMBL2633099 | 0.76 | ADAMTS5 (0.84) | MMP13MMP3NAT1GSK3BADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2020-09-10 | — | — | US | disclosed |
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3561077-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2019-09-12 | — | — | US | disclosed |
| EP-2406389-B1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3064595-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9434979-B2 | Methods and compositions for cell-proliferation-related disorders | SERVIER PHARMACEUTICALS LLC | 2016-09-06 | — | — | US | disclosed |
| EP-2491145-B1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150240286-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140187435-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130288284-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-07-18 | — | — | US | disclosed |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2012-05-17 | — | — | US | disclosed |
| WO-2011050210-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010105243-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711314-B2 | Methods for diagnosing IDH-mutant cell proliferation disorders | MKI67, IDH1, IDH3A | IDH1 2/4885MMP13 498/4885MMP3 544/4885 |
| US-10610125-B2 | Methods and compositions for cell-proliferation-related disorders | MKI67, BRCA1, CLN6 | IDH1 300/4885MMP13 1460/4885MMP3 1669/4885 |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885MMP13 1460/4885MMP3 1669/4885 |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885MMP13 1460/4885MMP3 1669/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885MMP13 1460/4885MMP3 1669/4885 |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, MKI67 | IDH1 2/4885MMP13 1038/4885MMP3 1005/4885 |
| US-20200281501-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885MMP13 1460/4885MMP3 1669/4885 |
| US-20190276894-A1 | METHOD FOR TREATING CELL PROLIFERATION RELATED DISORDERS | IDH2, IDH1, IDH3A | IDH1 2/4885MMP13 1465/4885MMP3 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.